Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect

Exp Hematol. 2017 Apr:48:1-11. doi: 10.1016/j.exphem.2016.12.004. Epub 2016 Dec 24.

Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) represents the only curative therapy for many haematological malignancies. Its curative potential is mostly attributed to the graft-versus-leukemia effect (GvL), which is mainly driven by donor T-cells. Donor lymphocyte infusions (DLI), likewise a second allo-HCT, have become a standard approach to treat AML and MDS relapses post allo-HCT. Although DLI have been used in this setting for decades, its effectivity and toxicity are still unpredictable in many patients. Over these recent years, new DLI strategies and therapies have been developed for AML and MDS. In this review, we will overview the recent use of DLI for AML and MDS, with up to date information from novel studies and research lines.

Publication types

  • Review

MeSH terms

  • Animals
  • Combined Modality Therapy
  • Graft vs Host Disease / etiology
  • Graft vs Leukemia Effect / immunology*
  • HLA Antigens / immunology
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Leukemia, Myeloid, Acute / complications
  • Leukemia, Myeloid, Acute / immunology*
  • Leukemia, Myeloid, Acute / therapy*
  • Lymphocyte Transfusion* / adverse effects
  • Lymphocyte Transfusion* / methods
  • Myelodysplastic Syndromes / complications
  • Myelodysplastic Syndromes / immunology*
  • Myelodysplastic Syndromes / therapy*
  • Retreatment
  • Tissue Donors*
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • HLA Antigens